4 hours Ago By Defense World Staff
Renaissance Technologies LLC lessened its position in Mesa Laboratories, Inc. (NASDAQ:MLAB – Free Report) by 44.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission.
The firm owned 7,500 shares of the medical instruments supplier’s stock after selling 5,900 shares during the period. Renaissance Technologies LLC owned approximately 0.14% of Mesa Laboratories worth $989,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of MLAB. Franklin Resources Inc. raised its holdings in shares of Mesa Laboratories by 27.
8% during the third quarter. Franklin Resources Inc. now owns 6,444 shares of the medical instruments supplier’s stock valued at $828,000 after buying an additional 1,403 shares during the last quarter.
Barclays PLC increased its position in Mesa Laboratories by 357.4% in the 3rd quarter. Barclays PLC now owns 8,837 shares of the medical instruments supplier’s stock valued at $1,148,000 after acquiring an additional 6,905 shares during the period.
Principal Financial Group Inc. raised its stake in Mesa Laboratories by 21.8% during the 3rd quarter.
Principal Financial Group Inc. now owns 35,107 shares of the medical instruments supplier’s stock valued at $4,559,000 after acquiring an additional 6,292 shares in the last quarter. JPMorgan Chase & Co.
boosted its position in Mesa Laboratories by 29.3% during the 3rd quarter. JPMorgan Chase & Co.
now owns 8,406 shares of the medical instruments supplier’s stock worth $1,092,000 after acquiring an additional 1,906 shares during the period. Finally, Pacer Advisors Inc. grew its stake in shares of Mesa Laboratories by 4.
3% in the fourth quarter. Pacer Advisors Inc. now owns 1,755 shares of the medical instruments supplier’s stock worth $231,000 after purchasing an additional 73 shares in the last quarter.
Institutional investors own 90.60% of the company’s stock. Insider Buying and Selling at Mesa LaboratoriesIn other news, CEO Gary M.
Owens sold 21,000 shares of the company’s stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $123.91, for a total value of $2,602,110.
00. Following the completion of the sale, the chief executive officer now owns 43,337 shares in the company, valued at $5,369,887.67.
This represents a 32.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.
4.40% of the stock is currently owned by corporate insiders. Mesa Laboratories Price PerformanceShares of NASDAQ MLAB opened at $115.
25 on Thursday. The stock has a market cap of $626.27 million, a P/E ratio of -2.
49 and a beta of 0.92. The firm’s 50-day simple moving average is $122.
02 and its 200 day simple moving average is $126.96. Mesa Laboratories, Inc.
has a fifty-two week low of $83.68 and a fifty-two week high of $155.12.
The company has a quick ratio of 0.53, a current ratio of 0.71 and a debt-to-equity ratio of 0.
61. Mesa Laboratories (NASDAQ:MLAB – Get Free Report) last released its earnings results on Tuesday, February 4th. The medical instruments supplier reported $2.
07 EPS for the quarter, beating the consensus estimate of $1.41 by $0.66.
Mesa Laboratories had a negative net margin of 104.92% and a positive return on equity of 30.23%.
Equities analysts expect that Mesa Laboratories, Inc. will post 8 EPS for the current year. Mesa Laboratories Announces DividendThe company also recently announced a quarterly dividend, which will be paid on Monday, June 16th.
Shareholders of record on Friday, May 30th will be given a $0.16 dividend. The ex-dividend date of this dividend is Friday, May 30th.
This represents a $0.64 dividend on an annualized basis and a yield of 0.56%.
Mesa Laboratories’s dividend payout ratio (DPR) is -1.38%. About Mesa Laboratories (Free Report)Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.Read MoreFive stocks we like better than Mesa LaboratoriesDividend Capture Strategy: What You Need to KnowWhy D-Wave’s Project With Davidson Is a Game-Changer For QuantumRussell 2000 Index, How Investors Use it For Profitable TradingHims & Hers Stock Soars on Novo Nordisk CollaborationDiversification Can Smooth Returns And Mitigate Portfolio RiskAmazon’s Earnings Will Make or Break the Stock’s Comeback.
